BNP (Nesiritide)

Brain Natriuretic Peptide (BNP-32) / Nesiritide (Natrecor)

Evidence & Status

  • Strong Human Evidence
  • Established

At a Glance

A cardiac hormone released by the ventricles under stress, and the basis for a widely used heart-failure biomarker. Its recombinant drug form, nesiritide (Natrecor), was FDA-approved in 2001 for acute heart failure but is now discontinued after a large outcomes trial found no mortality/rehospitalization benefit.

Plain English

Researchers study BNP (B-type Natriuretic Peptide) because it's one of the most clinically important cardiac biomarkers in medicine — when the heart is under stress, it releases BNP, and blood levels help clinicians assess how severe heart failure is. A synthetic version, Nesiritide, was FDA-approved in 2001 as a heart-failure treatment, but a large follow-up trial later found it didn't reduce death or hospital readmission compared to standard care, and it's now discontinued. NT-proBNP, often mentioned alongside BNP, is actually a separate fragment of the same precursor molecule, not another name for BNP itself.

Overview

Brain natriuretic peptide (BNP-32) is a 32-amino-acid peptide hormone secreted primarily by ventricular cardiomyocytes in response to increased wall tension. It shares receptor and mechanism with ANP (see companion entry) — both bind NPR-A to produce vasodilation, natriuresis, diuresis, and RAAS suppression. BNP is processed from a 108-aa proBNP precursor: NT-proBNP (the inactive 76-aa N-terminal fragment) is a distinct molecule from BNP-32, not an alias of it, and has its own longer half-life that makes it a useful biomarker. In a study of 1,586 emergency department patients with acute dyspnea, bedside BNP measurement distinguished cardiac from non-cardiac causes with reported accuracy of 83.4% at a 100 pg/mL cutoff and a negative predictive value of 96% below 50 pg/mL (Maisel et al., 2002) — a finding specific to that acute-dyspnea population, not a universal diagnostic cutoff. Nesiritide (Natrecor), recombinant human BNP with the identical 32-aa sequence, was FDA-approved in 2001 as an IV vasodilator for acute decompensated heart failure; FDA records currently list it as discontinued. In the large ASCEND-HF outcomes trial (n=7,141), nesiritide did not significantly reduce 30-day death or heart-failure rehospitalization compared with placebo (9.4% vs. 10.1%), and its dyspnea benefit was not statistically significant, with more hypotension observed. Native BNP-32 itself does not have a current FDA-approved drug-product context; nesiritide is a distinct, now-discontinued drug product built on the same sequence.

Research Summary

BNP's most impactful clinical role is as a diagnostic and prognostic biomarker: in a study of 1,586 emergency department patients, bedside BNP distinguished cardiac from non-cardiac dyspnea with 83.4% accuracy at a 100 pg/mL cutoff and 96% negative predictive value below 50 pg/mL (Maisel et al., 2002) — findings specific to that acute-care population. As a therapeutic agent, nesiritide (recombinant BNP-32) was FDA-approved in 2001 based on hemodynamic endpoints, but the larger ASCEND-HF outcomes trial (7,141 patients, 2011) found no statistically significant reduction in 30-day mortality or rehospitalization versus placebo, with more hypotension in the nesiritide arm; FDA records currently list Natrecor as discontinued. This illustrates that improving hemodynamic endpoints does not automatically translate into improved clinical outcomes. Native BNP-32 itself is not an FDA-approved drug product — nesiritide is a distinct, now-discontinued recombinant product built on the same sequence. NT-proBNP is a separate 76-amino-acid cleavage fragment of proBNP, not an alias of BNP-32, and is used as its own biomarker due to its longer half-life.

Research Areas

  • Heart failure biomarker
  • Acute decompensated heart failure
  • Cardiac hemodynamics
  • Natriuretic peptide biology
  • RAAS regulation

Safety & Risks

Serious Risks

  • Symptomatic hypotension — can worsen renal perfusion; avoid in cardiogenic shock or low baseline SBP
  • 2011 ASCEND-HF trial (n=7,141) found nesiritide did not significantly reduce 30-day mortality or rehospitalization vs. placebo, and produced more hypotension
  • Worsening renal function (debated in outcomes literature)

Reported Side Effects

  • Hypotension (most common, dose-dependent)
  • Headache
  • Nausea
  • Back pain
United States
Native BNP-32 is not itself an approved drug; nesiritide (Natrecor), a recombinant BNP-32 drug product, was FDA-approved in 2001 for acute decompensated heart failure and is currently listed by FDA as discontinued
United Kingdom
Not MHRA-approved (nesiritide); natriuretic peptide biomarker testing widely used
Australia
Not TGA-approved as a therapeutic agent
Canada
Not Health Canada-approved for therapeutic use

Citations & Sources